4.40

4.16% -0.17

Bioage Labs Inc (BIOA)

Overview News Price History Discussions Forecast

Bioage Labs Inc stock is traded at $4.40, with a volume of 119.53K. It is down -4.16% in the last 24 hours and down -18.28% over the past month. Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. Its Products are Azelaprag (BGE-105), an apelin receptor APJ agonist that increases weight loss and improves body composition combined with incretin drugs. and BGE-100 is targeting metabolic diseases and neuroinflammation.

Previous Close:

$4.57

Open:

$4.68

24h Volume:

119.53K

Relative Volume:

0.17

Market Cap:

$163.83M

Revenue:

Net Income/Loss:

P/E Ratio:

EPS:

Net Cash Flow:

1W Performance:

-4.58%

1M Performance:

-18.28%

6M Performance:

+0.00%

1Y Performance:

+0.00%

1-Day Range:

$4.36

$4.68

1-Week Range:

$4.32

$4.77

52-Week Range:

$3.85

$26.62

Bioage Labs Inc Stock (BIOA) Company Profile

Name

Bioage Labs Inc

Sector

Healthcare (1187)

Industry

Drug Manufacturers - Specialty & Generic (1)

Phone

510-806-1445

Address

1445A SOUTH 50TH STREET, RICHMOND

Employee

Twitter

Next Earnings Date

Latest SEC Filings

BIOA's Discussions on Twitter

Compare BIOA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BIOA Bioage Labs Inc	4.40	163.83M	0	0	0	0.00
ZTS Zoetis Inc	171.50	78.56B	9.15B	2.43B	2.31B	5.32
TAK Takeda Pharmaceutical Co Adr	13.54	43.15B	30.25B	1.37B	5.08B	0.4257
HLN Haleon Plc Adr	9.545	43.00B	14.26B	1.55B	0	0.3383
TEVA Teva Pharmaceutical Industries Ltd Adr	16.62	19.59B	16.54B	-1.64B	749.00M	-1.45
NBIX Neurocrine Biosciences Inc	123.74	15.24B	2.24B	385.90M	440.10M	3.73

Bioage Labs Inc Stock (BIOA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-10-24	Downgrade	Morgan Stanley	Overweight → Underweight
Dec-09-24	Downgrade	Citigroup	Buy → Neutral
Dec-09-24	Downgrade	Jefferies	Buy → Hold
Oct-21-24	Initiated	Citigroup	Buy
Oct-21-24	Initiated	Jefferies	Buy
Oct-21-24	Initiated	Morgan Stanley	Overweight

View All

Bioage Labs Inc Stock (BIOA) Latest News

09:46 AM

BioAge Labs (BIOA) Shares Plummet After Discontinuing Trial Just 2 Months After IPO– Hagens Berman - GlobeNewswire

09:46 AM

05:45 AM

BioAge Labs, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your RightsBIOA - PR Newswire

05:45 AM

Feb 06, 2025

Deadline Alert: BioAge Labs, Inc. (BIOA) Investors Who Lost - GlobeNewswire

Feb 06, 2025

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BioAge Labs - Markets Insider

Feb 06, 2025

Levi & Korsinsky Notifies BioAge Labs, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineBIOA - ACCESS Newswire

Feb 06, 2025

BIOA Investors Have Opportunity to Lead BioAge Labs, Inc. Securities Lawsuit - PR Newswire

Feb 06, 2025

Contact The Gross Law Firm by March 10, 2025 Deadline to Join Class Action Against BioAge Labs, Inc.(BIOA) - PR Newswire

Feb 06, 2025

Feb 05, 2025

ROSEN, A LEADING LAW FIRM, Encourages BioAge Labs, Inc. - GlobeNewswire

Feb 05, 2025

BIOA Deadline Alert: Kessler Topaz Meltzer & Check, LLP - GlobeNewswire

Feb 05, 2025

ROSEN, A LEADING LAW FIRM, Encourages BioAge Labs, Inc. Investors to Secure Counsel Before - The Bakersfield Californian

Feb 05, 2025

ROSEN, A LEADING LAW FIRM, Encourages BioAge Labs, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BIOA - GlobeNewswire Inc.

Feb 05, 2025